Solutions
One engine, four kinds of decision
Clinical pharmacology, clinical development, drug safety and research partners ask different questions. They all use the same virtual patients and the same evidence record.
Clinical pharmacology and MIDD
Choose the dose with the whole population in view
Sweep dose and schedule across a realistic cohort, see exposure and response by subgroup, and document the reasoning for your MIDD package.
- Population exposure and response with intervals
- Subgroup effects for age, organ function and genotype
- Surrogates checked against your reference models
SZ-0412 · 20, 40, 60 mg
- 20 mg ORR
- 19% (16–23%)
- 40 mg ORR
- 31% (27–35%)
- 60 mg ORR
- 34% (30–38%)
- 60 mg grade 3+ AE
- 15% (12–18%)
Clinical development
Rank protocols before the first site opens
Protova searches design options and shows which ones keep power while staying safe and inclusive, with the trade-offs written down.
- Ranked designs with stated trade-offs
- Sample size and power under realistic heterogeneity
- Inclusion criteria tested for equity
Phase 2b · 3 designs
- Design A
- 40 mg, n = 180, power 86%
- Design B
- 40 mg, n = 150, power 79%
- Design C
- 20/40 mg, n = 210, power 84%
Drug safety and pharmacovigilance
Look for rare risk where it hides
Vigila oversamples the subgroups that small trials miss and maps where predicted adverse-event risk concentrates.
- Rare-subgroup stress tests
- Exposure thresholds for monitoring plans
- Signals tracked against later outcomes in Evidra
Hepatic grade 3+
- Overall
- 0.4%
- At-risk cluster
- 3.1%
- Cluster share of cohort
- 1.2%
CROs and academic medical centres
Add simulation to the studies you run
Offer sponsors simulation-backed design work, or use Sanenza for research on under-represented populations.
- Per-study access for sponsor work
- Research access for academic groups (planned)
- Shared evidence records with sponsor approval
Sponsor study support
- Scope
- One protocol, two questions
- Duration
- 8 weeks
- Deliverable
- Design report and back-test
Compare
Which products each team uses first
| Team | First question | Products | Typical first output |
|---|---|---|---|
| Clinical pharmacology | Which dose and schedule? | Cohorta, Insilon, Evidra | Dose sweep with subgroup effects |
| Clinical development | Which protocol? | Protova, Insilon, Vigila | Ranked design shortlist |
| Drug safety | Where is the rare risk? | Vigila, Cohorta | Signal map and thresholds |
| Device and delivery | Where does the drug go? | Physova, Insilon | Regional exposure map |
| CROs and academia | How do we add simulation? | Any, by study | Study-specific report |
Start with your team's first question
Each briefing is built around one decision your team faces, so you can judge the method quickly.